Last reviewed · How we verify
NCT06823700
Safety and Effectiveness Study of SQ-Kyrin System for Functional Mitral Regurgitation in EU
NA trial testing SQ-Kyrin Transcatheter Mitral Valve Repair System in Functional Mitral Regurgitation in 34 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Shanghai Shenqi Medical Technology Co., Ltd |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 34 |
| Start date | 17 December 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- SQ-Kyrin Transcatheter Mitral Valve Repair System
Conditions studied
- Functional Mitral Regurgitation — all drugs for Functional Mitral Regurgitation →
Sponsor
Shanghai Shenqi Medical Technology Co., Ltd
Who can join
18 and older, any sex, with Functional Mitral Regurgitation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigation objective of this study is to evaluate the safety and effectiveness of the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter in the population of FMR patients and the accessories devices when used in conjunction with the Transcatheter Mitral Valve Clip Delivery System and Steerable Guide Catheter.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06823700
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Functional Mitral Regurgitation
Currently open trials in the same condition.
- NCT05991284 — Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation · Phase 4 · active not recruiting
- NCT05965258 — Phenotypic Classification of FMR With CMR · recruiting
- NCT03929913 — NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study · NA · active not recruiting
- NCT03706833 — Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial · NA · active not recruiting
- NCT03142152 — The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR · NA · recruiting
Other Shanghai Shenqi Medical Technology Co., Ltd trials
Trials by the same sponsor.
- NCT06320912 — Efficacy and Safety of Intraparenchymal Portal Vein Covered Stents in Treating Portal Hypertension and Its Complications · NA · not yet recruiting
- NCT06024525 — Verify Effectiveness and Safety of Paclitaxel-Coated Coronary Balloon Catheters Swide® · NA · not yet recruiting
- NCT07140822 — A Randomized Study of Cutting Balloon Catheter for CAD · NA · completed
- NCT06605313 — SQ-Kyrin-T First-in-man Feasibility Study · NA · active not recruiting
- NCT06467110 — Safety and Effectiveness Study of SQ-Kyrin TMVr System for Degenerated Mitral Regurgitation · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06823700 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Shenqi Medical Technology Co., Ltd
- Last refreshed: 12 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06823700.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing